TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02748746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bio Impedance Analysis Measurement
Description: Self-adhesive electrodes will be placed to related side's hand dorsum and foot dorsum regarding to calculate for left or right upper extremity's impedance. After completing the measurements for each side, results will be saved by device and documented on paper. A patient total measurement time lasts approximately 3 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bio Impedance Analysis Measurement
Description: Self-adhesive electrodes will be placed to related side's hand dorsum and foot dorsum regarding to calculate for left or right upper extremity's impedance. After completing the measurements for each side, results will be saved by device and documented on paper. A patient total measurement time lasts approximately 3 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Dielectric Constant Measurement
Description: In this study, TDC device (Moisture Meter-D compact-MMDc will be implemented to upper extremity both affected and unaffected side. 6 cm lower point of cubital crease, 8 cm upper point of cubital crease and 10 cm lower point of armpit will be marked on two sides with a soft pen before measurement. A gentle pressure must required to have accurate sub-tissue fluid percent. Triplicate measurements will be done and taken those average value for each point in order to reach sensitive screening. Computer software simultaneously save these measurements results automatically. A patient total measurement time approximately lasts 5 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue Dielectric Constant Measurement
Description: In this study, TDC device (Moisture Meter-D compact-MMDc will be implemented to upper extremity both affected and unaffected side. 6 cm lower point of cubital crease, 8 cm upper point of cubital crease and 10 cm lower point of armpit will be marked on two sides with a soft pen before measurement. A gentle pressure must required to have accurate sub-tissue fluid percent. Triplicate measurements will be done and taken those average value for each point in order to reach sensitive screening. Computer software simultaneously save these measurements results automatically. A patient total measurement time approximately lasts 5 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue Dielectric Constant Measurement
Description: In this study, TDC device (Moisture Meter-D compact-MMDc will be implemented to upper extremity both affected and unaffected side. 6 cm lower point of cubital crease, 8 cm upper point of cubital crease and 10 cm lower point of armpit will be marked on two sides with a soft pen before measurement. A gentle pressure must required to have accurate sub-tissue fluid percent. Triplicate measurements will be done and taken those average value for each point in order to reach sensitive screening. Computer software simultaneously save these measurements results automatically. A patient total measurement time approximately lasts 5 minutes.
Study: NCT02947360

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focused vascular ultrasound of the carotid arteries
Description: Emergency physicians and a trained research sonographer will perform a focused vascular ultrasound of the carotids (FOVUS) in patients presenting to the emergency department with chest pain. The diagnostic test characteristics (sensitivity, sensitivity, negative predictive value, positive predictive value and likelihood ratios) for FOVUS carotid plaque height will be determined in relation to our primary outcome (30-day major adverse cardiac events)
Study: NCT03015246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended release morphine
Description: Dose (tailored to each participant based on his/her pre-experimental opioid use amount) is administered in 3 divided daily doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Extended release morphine
Description: Dose (tailored to each participant based on his/her pre-experimental opioid use amount) is administered in 3 divided daily doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/Naloxone low dose
Description: Buprenorphine/Naloxone dose of 1.4/0.36 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/Naloxone low dose
Description: Buprenorphine/Naloxone dose of 1.4/0.36 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/Naloxone moderate dose
Description: Buprenorphine/Naloxone dose of 4.2/1.08 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/Naloxone moderate dose
Description: Buprenorphine/Naloxone dose of 4.2/1.08 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/Naloxone high dose
Description: Buprenorphine/Naloxone dose of 12.8/3.16 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/Naloxone high dose
Description: Buprenorphine/Naloxone dose of 12.8/3.16 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active stressor
Description: Yohimbine hydrochloride 60mg + Hydrocortisone 20mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active stressor
Description: Yohimbine hydrochloride 60mg + Hydrocortisone 20mg tablet
Study: NCT04062097

Intervention type: DRUG
Intervention: Dabigatran Etexilate Oral Capsule [Pradaxa]
Description: Dabigatran is the most frequently used direct thrombin inhibitor in secondary stroke prevention in patients with atrial fibrillation.
Study: NCT03015246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active stressor
Description: Yohimbine hydrochloride 60mg + Hydrocortisone 20mg tablet
Study: NCT03062293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Re-adaptive Exercise Device
Description: Exercise intervention 3 times per week for up to 30min. Difficulty and time will be progressed as indicated by clinical presentation, assessed by the Physiotherapist team.
Study: NCT02233023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromocriptine and other dopamine agonists
Study: NCT02240355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6885247
Description: oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6885247
Description: oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6885247
Description: oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: oral solution
Study: NCT00959738

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Diverting loop ileostomy with rod
Description: Diverting loop ileostomy with rod

Intervention type: PROCEDURE
Group type: OTHER
Intervention: diverting loop ileostomy without rod
Description: diverting loop ileostomy without rod
Study: NCT00858637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-196
Description: Tablets of 3 g to 12 g/day (3 times a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Simvastatin
Description: Tablets once a day, for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Simvastatin
Description: Tablets once a day, for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Simvastatin
Description: Tablets once a day, for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Tablets of 10 mg to 40 mg/day (once a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of MCI-196
Description: Tablets 3 times a day for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of MCI-196
Description: Tablets 3 times a day for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of MCI-196
Description: Tablets 3 times a day for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
Study: NCT02210260

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal and infusion of local anaesthetic
Description: Spinal anaesthetic will be performed in the lateral position using a midline approach. L3/4 interspace will be identified using Tuffier's as the anatomical landmark. After confirmation of correct placement using a 25G Whitacre needle, 12.5 mg of hyperbaric Bupivacaine in a mixture with 500mcg Diamorphine will be injected intrathecally.~PLUS~Painbuster® catheters will be placed by the surgeon at the end of the procedure in a location determined by the surgical approach. A bolus dose of 20ml 0.25% L-Bupivacaine will be injected down the catheters prior to the connection of the elastomeric pump which will also contain 270ml 0.25% L-Bupivacaine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous infusion of local anaesthetic
Description: A Painbuster® catheter will be placed by the surgeon at the end of the procedure in a location determined by the surgical approach. A bolus dose of 20ml 0.25% L-Bupivacaine will be injected down the catheters prior to the connection of the elastomeric pump which will also contain 270ml 0.25% L-Bupivacaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Study: NCT03548012

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Carer Support Needs Assessment Tool (CSNAT) intervention
Description: The CSNAT intervention is a caregiver-led approach where the caregiver first identifies his/her needs of support in the CSNAT, which consists of 14 support domains. Then the practitioner facilitates the intervention where the caregiver prioritizes which domains to discuss. In the conversation, the caregiver's domain priorities and subsequently identified support needs are discussed with the practitioner to agree on actions/solutions and a shared action plan. The intervention will be offered each caregiver twice: the first time between 0 and 13 days after enrollment, and the second time between 15 and 27 days after enrollment.
Study: NCT02210260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diamorphine
Description: 500mcg

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A Painbuster® catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A Painbuster® catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 25G Whitacre needle
Study: NCT01578122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 25mmHg ECS
Description: Thigh-length graduated elastic compression stockings applying 25 mmhg of targeted pressure at the ankle worn daily (from morning to night) for two years.~Before receiving the randomly allocated treatment, each patient will wear cotton, class III Varisma Comfort® stay-up stockings (20-36 mm Hg).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 35 mmHg ECS
Description: Thigh-length graduated elastic compression stockings applying 35mmhg of pressure at the ankle worn daily (from morning to night) for two years Before receiving the randomly allocated treatment, each patient will wear cotton, class III Varisma Comfort® stay-up stockings (20-36 mm Hg).
Study: NCT02913378

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteosynthesis with locking plate
Description: Open reduction and osteosynthesis with locking plate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sling
Description: Conservative treatment with sling and rehabilitation
Study: NCT02639520

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canephron® N
Description: 2 tablets 3 times a day for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosfomycin trometamol
Description: 1 sachet of 8 g of granules; one single dose on Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canephron® N-placebo
Description: 2 tablets 3 times a day for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosfomycin trometamol-placebo
Description: 1 sachet of 8 g of granules; one single dose on Day 1
Study: NCT03803384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Description: Oxygen supply during ESWT, once with the prescribed constant oxygen flow and once using an auto-regulated oxygen flow system setting the SpO2 target at 92%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Description: Oxygen supply during ESWT, once with the prescribed constant oxygen flow and once using an auto-regulated oxygen flow system setting the SpO2 target at 92%.
Study: NCT03910114

Intervention type: DRUG
Intervention: Magnevist
Description: GBCA enhancement

Intervention type: DRUG
Intervention: Dotarem
Description: GBCA enhancement

Intervention type: DRUG
Intervention: Gadovist
Description: GBCA enhancement
Study: NCT01061502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Procellera (Bioelectric Wound Dressing)
Description: Dressing used on one-half of the donor graft site. Dressing changes every 5-7 days, more frequently if needed

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Opsite (Transparent Adhesive Dressing)
Description: Semi-occlusive wound dressing placed on one-half of the skin graft donor site. Dressing change every 5-7 days, more frequently if needed.
Study: NCT03388047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopy with Polyscope (Polydiagnost TM) coupled with Multi-Spectral Imaging light-source
Description: During surveillance endoscopy procedure, the endoscopist will insert the multispectral endoscopy probe through the working channel and use this to inspect the Barrett's oesophagus segment and any visible lesions
Study: NCT04239690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Micromethods for blood sample analysis
Description: Micromethods in the intervention arm are applied aiming to achieve a mean reduction of 50 % of sampled blood volume during the first two postnatal weeks as compared to standard clinical blood sampling analyses
Study: NCT04180332

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: 5ml of venous blood was taken from the ante cubital vein from each of the study subjects
Study: NCT02533271

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy with neoadjuvant chemotherapy
Description: Short-course radiotherapy with 4 cycles of neoadjuvant chemotherapy

Intervention type: RADIATION
Group type: OTHER
Intervention: Long-term chemoradiotherapy
Description: Standard chemoradiotherapy
Study: NCT01057043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsatile cupping
Description: 8 sessions cupping in 4 weeks, administered by a cupping machine. Cupping is administered in each session for 15 minutes with silicon cupping glasses to the knee (osteoarthritis) and the lower back.
Study: NCT04415099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle fatigue protocol
Description: Tibialis posterior was fatigued using 2 exercises:~1. Unilateral heel raise exercise~2. Close chain resisted foot adduction exercise
Study: NCT04206293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvederm® VOLITE
Description: 1 mL of Juvéderm® VOLITE contains hyaluronic acid gel 12.0 milligram (mg), lidocaine hydrochloride 3.0 mg in a phosphate buffer pH 7.2 q.s. 1 mL (or gram).
Study: NCT00962130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring system
Description: one or two monitors will be placed in the tissue to be transferred
Study: NCT00724516

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel Breast Compression Paddle
Description: Instead of using the regular wire localization mammography compression paddle, a new breast compression paddle will be used. The new breast compression paddle is similar to a tennis racquet. It consists of crossing plastic strings that are strung tightly in a frame. The needle/wire can be inserted anywhere between the strings.
Study: NCT04062097

Intervention type: DRUG
Intervention: Idarucizumab 2.5 GM/50 ML Intravenous Solution [PRAXBIND]
Description: Idarucizumab is the current standard therapy in patients with intracranial bleeding under anticoagulation with dabigatran.
Study: NCT03086174

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: humanized anti-PD-1 monoclonal antibody Toripalimab
Description: humanized anti-PD-1 monoclonal antibody Toripalimab is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
Study: NCT02850536

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CEA CAR-T cells
Description: Gene modified patient T cells
Study: NCT01626261

Intervention type: DEVICE
Intervention: Magnetic and electric field´s impact on the implant
Description: Examination of magnetic and electric field's impact on the implant regarding: stability detection threshold using different strength of magnetic and electric field
Study: NCT03144492

Intervention type: BIOLOGICAL
Intervention: Blood volume collected specifically for this study
Description: The subject will be sitting in a chair, and a needle will be inserted into a vein in their arm. Study Team will draw about 45ml or 3 tablespoons of whole blood for research.
Study: NCT01436279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: 200 mg po 20-24 hours prior to the procedure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: osmotic dilators
Description: osmotic dilators placed in the cervix 20-24 hours prior to the procedure
Study: NCT03015246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active stressor
Description: Yohimbine hydrochloride 60mg + Hydrocortisone 20mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo stressor
Description: Lactose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo stressor
Description: Lactose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo stressor
Description: Lactose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo stressor
Description: Lactose
Study: NCT01169350

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo 18F FDG and 18F FMISO PET/CT scans

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-fluoromisonidazole
Description: Undergo 18F FDG and 18F FMISO PET/CT scans

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo 18F FDG and 18F FMISO PET/CT scans

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo 18F FDG and 18F FMISO PET/CT scans

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01834833

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up
Description: Evaluation by a cardiologist using echocardiography, completed by education of the patient if necessary
Study: NCT00324220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD0103
Description: MGCD0103 Oral administration 3 times per week.
Study: NCT03295019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Oral Spray
Description: HA formulation of FDA listed ingredients

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Spray
Description: Placebo formulation without the active ingredients
Study: NCT04062097

Intervention type: DRUG
Intervention: Vitamin K antagonist
Description: This drug group includes the active substances phenprocoumon and warfarin.
Study: NCT01712204

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsule BID for 16 Weeks
Study: NCT00383994

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK Cell Infusion
Description: NK cells will be infused one week after the fourth dose of Rituximab and GM-CSF.
Study: NCT01528605

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo, one gelatine capsule containing starch per day, for 96 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low lutein
Description: one gelatine capsule containing 10mg lutein per day, for 96 weeks
Study: NCT01712204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-201
Description: AC-201 50mg Capsule BID for 16 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat 80 mg QD for 16 Weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Febuxostat
Description: Febuxostat 80 mg QD for 16 Weeks
Study: NCT01224743

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blend 1
Description: Blend 1 consists of a combination of Juice Plus+® Orchard (Fruit), Garden (Vegetable), and Vineyard (Berry) blends

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blend 2
Description: Blend 2 consists of a combination of Juice Plus+® Orchard (Fruit) and Garden (Vegetable) blends

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules are provided by the study sponsor and are identical in appearance to active treatments to ensure blinding.